Effects of a prostaglandin DP receptor agonist, AL-6598, on aqueous humor dynamics in a nonhuman primate model of glaucoma.

This study examines, in 11 cynomolgus monkeys with unilateral laser-induced glaucoma, the ocular hypotensive mechanism of action of AL-6598, partial agonist at the DP and EP prostanoid receptors. In a crossover fashion, both eyes of each monkey were dosed twice daily with 25 microL of either AL-6598 0.01% or vehicle for 2 days and on the morning of the 3rd day. Measurements were made on day 3 of each treatment. Alternative treatments were separated by at least 2 weeks. Intraocular pressures (IOPs) were measured by pneumatonometry and aqueous flow and outflow facility by fluorophotometry. Uveoscleral outflow was calculated mathematically. In the normotensive eyes, compared to vehicle treatment, AL-6598 decreased IOP from 22.5 +/- 0.7 to 18.7 +/- 0.9 mmHg (P = 0.006), increased uveoscleral outflow from 0.47 +/- 0.17 to 1.22 +/- 0.17 microL/min (P = 0.03), and increased aqueous flow from 1.49 +/- 0.10 to 1.93 +/- 0.13 microL/min (P = 0.01). No measurement in AL-6598-treated hypertensive eyes was significantly different from vehicle treatment. It is concluded that AL-6598 reduces IOP by increasing uveoscleral outflow in normotensive eyes of ketamine-sedated monkeys, despite an increase in aqueous flow. This effect is different from that of PGD(2), which decreases aqueous flow, and of the selective DP receptor agonist, BW245C, which increases both outflow facility and uveoscleral outflow in addition to decreasing aqueous flow.

[1]  C. Camras,et al.  Effects of Travoprost on Aqueous Humor Dynamics in Monkeys , 2005, Journal of glaucoma.

[2]  M. Araie,et al.  Effect of topical prostaglandin D2 on the aqueous humor dynamics in rabbits , 2005, Graefe's Archive for Clinical and Experimental Ophthalmology.

[3]  Gary W. Williams,et al.  Molecular pharmacology of the DP/EP2 class prostaglandin AL-6598 and quantitative autoradiographic visualization of DP and EP2 receptor sites in human eyes. , 2004, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[4]  C. Camras,et al.  Increase in outflow facility with unoprostone treatment in ocular hypertensive patients. , 2004, Archives of ophthalmology.

[5]  J. McLaren,et al.  Mechanism of ocular hypotensive action of bimatoprost (Lumigan) in patients with ocular hypertension or glaucoma. , 2004, Ophthalmology.

[6]  M. Kageyama,et al.  Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug. , 2004, Experimental eye research.

[7]  O. Hayaishi,et al.  Effects of prostaglandin D2 and its analogue, BW245C, on intraocular pressure in humans , 2004, Graefe's Archive for Clinical and Experimental Ophthalmology.

[8]  C. Camras,et al.  Bimatoprost and travoprost: a review of recent studies of two new glaucoma drugs. , 2002, Survey of ophthalmology.

[9]  P. Kaufman,et al.  Effects of prostaglandins on the aqueous humor outflow pathways. , 2002, Survey of ophthalmology.

[10]  L. Desantis,et al.  Identification and characterization of the ocular hypotensive efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist, and AL-6598, a DP prostaglandin receptor agonist. , 2002, Survey of ophthalmology.

[11]  M. Yablonski,et al.  Aqueous Humor Dynamics in Ocular Hypertensive Patients , 2002, Journal of glaucoma.

[12]  Gary W. Williams,et al.  3-Oxa-15-cyclohexyl prostaglandin DP receptor agonists as topical antiglaucoma agents. , 2002, Bioorganic & medicinal chemistry.

[13]  R. Brubaker.  Mechanism of action of bimatoprost (Lumigan). , 2001, Survey of ophthalmology.

[14]  R. Brubaker,et al.  Effects of AGN 192024, a new ocular hypotensive agent, on aqueous dynamics. , 2001, American journal of ophthalmology.

[15]  J. Crider,et al.  Affinities, selectivities, potencies, and intrinsic activities of natural and synthetic prostanoids using endogenous receptors: focus on DP class prostanoids. , 2000, The Journal of pharmacology and experimental therapeutics.

[16]  M. Yablonski,et al.  Aqueous humor dynamics in monkeys with laser-induced glaucoma. , 2000, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[17]  P. D. G. K. Krieglstein.  Glaucoma Update VI , 1999, Springer Berlin Heidelberg.

[18]  Y. Kitazawa,et al.  A comparative study of latanoprost (Xalatan) and isopropyl unoprostone (Rescula) in normal and glaucomatous monkey eyes. , 1998, Japanese journal of ophthalmology.

[19]  A. Alm,et al.  Effects on intraocular pressure and aqueous flow of various dose regimens of latanoprost in human eyes. , 2009, Acta ophthalmologica Scandinavica.

[20]  R. Brubaker,et al.  Effects of exogenous prostaglandins on aqueous humor dynamics and blood-aqueous barrier function. , 1997, Survey of ophthalmology.

[21]  A. Alm,et al.  Initial clinical studies with prostaglandins and their analogues. , 1997, Survey of ophthalmology.

[22]  H. Mishima,et al.  Circadian intraocular pressure management with latanoprost: diurnal and nocturnal intraocular pressure reduction and increased uveoscleral outflow. , 1997, Survey of ophthalmology.

[23]  D. Jackson,et al.  Effects of BW A868C, a selective prostaglandin DP receptor antagonist, in dog isolated vascular preparations. , 1996, European journal of pharmacology.

[24]  M. Yablonski,et al.  Prostaglandin A2 increases uveoscleral outflow and trabecular outflow facility in the cat. , 1995, Experimental eye research.

[25]  L. Roberts,et al.  Effects of a selective DP receptor agonist (BW 245C) and antagonist (BW A868C) on the canine colonic epithelium: an argument for a different DP receptor? , 1995, The Journal of pharmacology and experimental therapeutics.

[26]  D. Crankshaw,et al.  Functional characterization of the prostanoid DP receptor in human myometrium. , 1995, European journal of pharmacology.

[27]  M. Kageyama,et al.  Selective prostaglandin D2 receptor stimulation elicits ocular hypotensive effects in rabbits and cats. , 1995, European journal of pharmacology.

[28]  B. Sjöquist,et al.  Preclinical pharmacology of latanoprost, a phenyl-substituted PGF2a analogue , 1995 .

[29]  R. Brubaker,et al.  The effects on aqueous dynamics of PhXA41, a new prostaglandin F2 alpha analogue, after topical application in normal and ocular hypertensive human eyes. , 1993, Archives of ophthalmology.

[30]  M. Yablonski,et al.  Effects of PhXA41, A New Prostaglandin F2α Analog, on Aqueous Humor Dynamics in Human Eyes , 1993 .

[31]  M. Abelson,et al.  Conjunctivitis of allergic origin: immunologic mechanisms and current approaches to therapy. , 1993, Survey of ophthalmology.

[32]  D. Woodward,et al.  Further studies on ocular responses to DP receptor stimulation. , 1993, European journal of pharmacology.

[33]  M. Takase,et al.  [A mechanism for reducing intraocular pressure in normal volunteers using UF-021, a prostaglandin-related compound]. , 1992, Nippon Ganka Gakkai zasshi.

[34]  P. Kaufman,et al.  The DP‐Receptor Agonist SQ27986 Raises but Does Not Lower Intraocular Pressure in Ocular Normotensive Monkeys , 1992 .

[35]  A. Alm,et al.  PhXA34, a new potent ocular hypotensive drug. A study on dose-response relationship and on aqueous humor dynamics in healthy volunteers. , 1991, Archives of ophthalmology.

[36]  M. Araie,et al.  Effects of topical application of UF-021, a novel prostaglandin derivative, on aqueous humor dynamics in normal human eyes. , 1991, Japanese journal of ophthalmology.

[37]  D. Woodward,et al.  Studies on the ocular pharmacology of prostaglandin D2. , 1990, Investigative ophthalmology & visual science.

[38]  A. Bill,et al.  The pressures in the episcleral veins, Schlemm's canal and the trabecular meshwork in monkeys: effects of changes in intraocular pressure. , 1989, Experimental eye research.

[39]  P. Kaufman,et al.  Prostaglandin F2α increases uveoscleral outflow in the cynomolgus monkey , 1989 .

[40]  A. Alm,et al.  Prostaglandin F2 alpha-isopropylester eye drops: effects in normal human eyes. , 1989, The British journal of ophthalmology.

[41]  M. Yablonski,et al.  Trabecular outflow facility determined by fluorophotometry in human subjects. , 1989, Experimental eye research.

[42]  A. Robertson,et al.  The antagonism by BW A868C of PGD2 and BW245C activation of human platelet adenylate cyclase , 1989, British journal of pharmacology.

[43]  L. Bito,et al.  The ocular effects of prostaglandins and other eicosanoids. , 1989, Progress in clinical and biological research.

[44]  O. Hayaishi,et al.  Prostaglandin D2 reduces intraocular pressure. , 1988, British Journal of Ophthalmology.

[45]  O. Hayaishi,et al.  Effects of prostaglandin D2 and its analogues on intraocular pressure in rabbits. , 1988, Japanese journal of ophthalmology.

[46]  M. Yablonski,et al.  Fluorophotometric study of intravenous carbonic anhydrase inhibitors in rabbits. , 1987, Investigative ophthalmology & visual science.

[47]  J. Rosenthal,et al.  Multiple dosing of prostaglandin F2 alpha or epinephrine on cynomolgus monkey eyes. I. Aqueous humor dynamics. , 1987, Investigative ophthalmology & visual science.

[48]  S. Podos,et al.  Intraocular pressure effects of multiple doses of drugs applied to glaucomatous monkey eyes. , 1987, Archives of ophthalmology.

[49]  P. Kaufman,et al.  Effects of topical PGF2α on aqueous humor dynamics in cynomolgus monkeys , 1987 .

[50]  S. Podos,et al.  Pharmacologic Alteration of Aqueous Humor Dynamics in Normotensive and Glaucomatous Monkey Eyes , 1987 .

[51]  P. Kulkarni,et al.  Prostaglandins E3 and D3 lower intraocular pressure. , 1985, Investigative ophthalmology & visual science.

[52]  S. Podos,et al.  Effect of prostaglandin F2 alpha on aqueous humor dynamics of rabbit, cat, and monkey. , 1984, Investigative ophthalmology & visual science.

[53]  P. Kaufman,et al.  The cynomolgus monkey as a model for orbital research. III. Effects on ocular physiology of lateral orbitotomy and isolation of the ciliary ganglion. , 1984, Current eye research.

[54]  M. Abelson,et al.  Aspirin therapy in vernal conjunctivitis. , 1983, American journal of ophthalmology.

[55]  R. Brubaker.  The flow of aqueous humor in the human eye. , 1982, Transactions of the American Ophthalmological Society.

[56]  B. Becker,et al.  Aqueous humor dynamics; theoretical considerations. , 1956, American journal of ophthalmology.